S. Zanoli

发表

Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutant.

M. Radi, C. Tintori, F. Musumeci, 2013, Journal of medicinal chemistry.

Inhibition of subgenomic hepatitis C virus RNA replication by acridone derivatives: identification of an NS3 helicase inhibitor.

Barbara Gatto, Jan Paeshuyse, Giuseppe Manfroni, 2009, Journal of medicinal chemistry.

Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.

A. Bergamini, E. Novellino, A. Coluccia, 2007, Journal of medicinal chemistry.

Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.

M. Radi, S. Zanoli, G. Maga, 2009, Journal of medicinal chemistry.

Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.

E. Novellino, A. Lavecchia, A. Coluccia, 2009, Journal of medicinal chemistry.

Toward the Discovery of Novel Anti‐HIV Drugs. Second‐Generation Inhibitors of the Cellular ATPase DDX3 with Improved Anti‐HIV Activity: Synthesis, Structure–Activity Relationship Analysis, Cytotoxicity Studies, and Target Validation

F. Baldanti, M. Radi, S. Zanoli, 2011, ChemMedChem.

5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.

A. Mai, S. Zanoli, G. Maga, 2008, Journal of medicinal chemistry.

Non-nucleoside HIV-1 reverse transcriptase inhibitors di-halo-indolyl aryl sulfones achieve tight binding to drug-resistant mutants by targeting the enzyme-substrate complex.

S. Zanoli, G. Maga, R. Silvestri, 2009, Antiviral research.

Discovery of non-nucleoside inhibitors of HIV-1 reverse transcriptase competing with the nucleotide substrate.

M. Radi, S. Zanoli, G. Maga, 2007, Angewandte Chemie.

Targeting the human DEAD-box polypeptide 3 (DDX3) RNA helicase as a novel strategy to inhibit viral replication.

U. Dietrich, M. Radi, S. Zanoli, 2011, Current medicinal chemistry.

Discovery of potent nucleotide-mimicking competitive inhibitors of hepatitis C virus NS3 helicase.

E. Novellino, S. Zanoli, G. Maga, 2011, Bioorganic & medicinal chemistry letters.

Year : 2005 Incorporation of non-nucleoside triphosphate analogues opposite to an abasic site by human DNA polymerases beta and lambda

E. Crespan, S. Zanoli, G. Maga, 2006 .

Incorporation of non-nucleoside triphosphate analogues opposite to an abasic site by human DNA polymerases β and λ

E. Crespan, S. Zanoli, G. Maga, 2005, Nucleic acids research.

Double Tibiofibular Synostosis (Fibula pro Tibia) for Non-Union and Delayed Union of the Tibia: END-RESULT REVIEW OF ONE HUNDRED SEVENTY-ONE CASES

S. Zanoli, M. Campanacci, 1966 .

Design and Synthesis of Thiadiazoles and Thiazoles Targeting the Bcr‐Abl T315I Mutant: from Docking False Positives to ATP‐Noncompetitive Inhibitors

Fabrizio Manetti, Maurizio Botta, Marco Radi, 2010, ChemMedChem.

Nerve growth factor protects human keratinocytes from ultraviolet-B-induced apoptosis.

S. Zanoli, A. Giannetti, A. Marconi, 1999, The Journal of investigative dermatology.

Current Advances in the Development of Anticancer Drugs Targeting Tyrosine Kinases of the Src Family

C. Brullo, E. Crespan, S. Zanoli, 2008 .

Towards novel S-DABOC inhibitors: synthesis, biological investigation, and molecular modeling studies.

M. Radi, S. Zanoli, G. Maga, 2008, Bioorganic & medicinal chemistry letters.

A Multidisciplinary Approach for the Identification of Novel HIV‐1 Non‐Nucleoside Reverse Transcriptase Inhibitors: S‐DABOCs and DAVPs

Maurizio Botta, Marco Radi, Mercedes Armand-Ugón, 2008, ChemMedChem.

High Potency of Indolyl Aryl Sulfone Nonnucleoside Inhibitors towards Drug-Resistant Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutants Is Due to Selective Targeting of Different Mechanistic Forms of the Enzyme

E. Crespan, S. Zanoli, G. Maga, 2005, Antimicrobial Agents and Chemotherapy.

Dual Src and Abl inhibitors target wild type Abl and the AblT315I Imatinib-resistant mutant with different mechanisms.

M. Radi, E. Crespan, S. Zanoli, 2010, Bioorganic & medicinal chemistry.

Event Generators for High-Energy Physics Experiments

M. Baker, P. Machado, D. Soldin, 2022, 2203.11110.

Slow‐, Tight‐Binding HIV‐1 Reverse Transcriptase Non‐Nucleoside Inhibitors Highly Active against Drug‐Resistant Mutants

Gianluca Sbardella, Antonello Mai, Imma Clotet-Codina, 2007, ChemMedChem.

Enantioselective binding of second generation pyrrolobenzoxazepinones to the catalytic ternary complex of HIV-1 RT wild-type and L100I and K103N drug resistant mutants.

E. Novellino, S. Zanoli, G. Maga, 2011, Bioorganic & medicinal chemistry letters.

Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.

A. Bergamini, E. Novellino, S. Zanoli, 2009, Journal of medicinal chemistry.

N2‐Benzyloxycarbonylguan‐9‐yl Acetic Acid Derivatives as HIV‐1 Reverse Transcriptase Non‐Nucleoside Inhibitors with Decreased Loss of Potency Against Common Drug‐Resistance Mutations.

S. Zanoli, G. Maga, N. Howarth, 2007, ChemMedChem.

Event Generators for High-Energy Physics Experiments

M. Baker, P. Machado, D. Soldin, 2022, 2203.11110.

Rational Q-systems at root of unity I. Closed chains

M. Baker, P. Machado, D. Soldin, 2023, SciPost Physics.